Results 201 to 210 of about 89,305 (304)

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Advances in immunotherapy and targeted therapy for nasopharyngeal carcinoma: Current progress and combined approaches (Review). [PDF]

Oncol Rep
Yang Z, Liu H, Chen M, Zhang L, Gong M, Yu R.   +5 more
europepmc   +1 more source

Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose ...
Reyad Dada, Refaei Belal Ibrahim
wiley   +1 more source

Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab. [PDF]

Diabetes Care
Mathieu C, Mathieu C, Sims EK, Chatenoud L, James EA, Atkinson MA, Herold KC.   +6 more
europepmc   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 872-880, April 2026.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Oral Bioavailability of Monoclonal Antibody. [PDF]

Pharmaceutics
Verma A, Wu S, Shah DK.
europepmc   +1 more source

Clinical Significance of Endoscopic Improvement at 6 Months in Patients With Ulcerative Colitis Treated With Ustekinumab: A Retrospective Real‐world Analysis

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives Ustekinumab (UST), an anti‐interleukin‐12/23 p40 monoclonal antibody, has emerged as an effective therapeutic option for patients with moderate to severe ulcerative colitis (UC). However, early predictors of long‐term treatment response remain unclear.
Hiromu Morikubo, Minoru Matsuura, Haruka Komatsu, Takeshi Fujima, Ryota Ogihara, Noriaki Oguri, Tatsuya Mitsui, Daisuke Saito, Mari Hayashida, Jun Miyoshi, Tadakazu Hisamatsu   +10 more
wiley   +1 more source

GB20-5A8-31, an anti-TL1A antibody for treating inflammatory bowel disease. [PDF]

Front Immunol
Huang Y, You Q, Yao T, Tong Y, Yang X, Zhang X, Huang X, Chen Q, Lu F, Li H, Wang J, Qin S.   +11 more
europepmc   +1 more source

Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model. [PDF]

J Virol
Yu W, He X, Zhao J, Dou Y, Hu T, Chen X, Ma X, Wang X, Hu S, Hu J, Liu X, Hu Z.   +11 more
europepmc   +1 more source

Feeding Behaviour in the KPC Model of Pancreatic Cancer‐Associated Cachexia: Alteration of Spontaneous and Evoked Feeding Behaviours

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background The KPC mouse model of pancreatic cancer is gaining use in research, but detailed understanding of ingestive behaviour changes in this and other cachexia models is limited. Methods Male C57BL/6 J mice (7 weeks) were maintained under standard feed (PicoLab5L0D) and housing conditions (12:12 h; Light:Dark).
Fateema Muzaffar, William F. Colmers, Vickie E. Baracos   +2 more
wiley   +1 more source